Following a successful Phase 3 trial in August that showed Merck and Moderna's personalized mRNA cancer vaccine significantly delayed melanoma recurrence and metastatic disease, the companies are preparing to file for approval. While patient Gary Keblish remains cancer-free and teaching after partic